The laboratory services company is scheduled to report second-quarter earnings on Aug. 1. On average, analysts expect earnings of 49 cents a share on revenue of $539.5 million."PKI's genomics strategy centers on offering unique services for the front and back ends of the NGS workflow," Bank of America Merrill Lynch analysts wrote in a May 15 report. "At the front end, the recent Caliper acquisition provides automated liquid handling and NGS sample preparation solutions, and while this market has become more competitive, PKI noted that pricing remains healthy. Beyond NGS, Caliper also adds new in vivo imaging technologies that complement PKI's pharma portfolio. On the back end, PKI believes that its emerging informatics business will gain traction over time as it aids with data access, storage, transfer and analysis, with a goal of facilitating the transition of NGS into the clinic. Management believes that this is roughly a $500 market opportunity, and expects to launch new data analysis products later this year." Forward Annual Dividend Yield: 1.1% -- Written by Alexandra Zendrian
>To contact the writer of this article, click here: Alexandra Zendrian >To submit a news tip, send an email to: email@example.com. >To follow the writer on Twitter, go to Alexandra Zendrian.